American journal of respiratory and critical care medicine
-
Am. J. Respir. Crit. Care Med. · Jan 2018
Comparative StudyDisease Staging and Prognosis in Smokers Using Deep Learning in Chest Computed Tomography.
Deep learning is a powerful tool that may allow for improved outcome prediction. ⋯ A deep-learning approach that uses only computed tomography imaging data can identify those smokers who have COPD and predict who are most likely to have ARD events and those with the highest mortality. At a population level CNN analysis may be a powerful tool for risk assessment.
-
Am. J. Respir. Crit. Care Med. · Jan 2018
Randomized Controlled Trial Multicenter StudyTezacaftor/Ivacaftor in Subjects with Cystic Fibrosis and F508del/F508del-CFTR or F508del/G551D-CFTR.
Tezacaftor (formerly VX-661) is an investigational small molecule that improves processing and trafficking of the cystic fibrosis transmembrane conductance regulator (CFTR) in vitro, and improves CFTR function alone and in combination with ivacaftor. ⋯ These results support continued clinical development of tezacaftor (100 mg every day) in combination with ivacaftor (150 mg every 12 h) in subjects with cystic fibrosis. Clinical trial registered with www.clinicaltrials.gov (NCT01531673).